Why Longitudinal Data May Be the Real Moat in Longevity
Longevity companies often talk as if their advantage lies in a proprietary clock, a sharper scan, a larger omics panel, […]
Analysis
Longevity Capital in 2026: The Four Buckets Still Getting Funded
There is a temptation to talk about longevity investing as if it were a single sector. It is not. The
Are GLP-1s the First Longevity Drugs — or Just the First Big Proxy?
Few drug classes have moved from endocrinology into so many neighboring territories so quickly. What began as a diabetes story